A Novel SARS-CoV-2-Derived Infectious Vector System
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19. The development of antiviral drugs for COVID-19 has been hampered by the requirement of a biosafety level 3 (BSL3) laboratory for experiments related to SARS-CoV-2, and by the lack of easy and precise me...
Saved in:
Main Authors: | Ghada Elfayres, Yong Xiao, Qinghua Pan, Chen Liang, Benoit Barbeau, Lionel Berthoux |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-06-01
|
Series: | Microbiology Research |
Subjects: | |
Online Access: | https://www.mdpi.com/2036-7481/16/6/125 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
SARS-CoV-2 Replication Revisited: Molecular Insights and Current and Emerging Antiviral Strategies
by: Bryan John J. Subong, et al.
Published: (2025-05-01) -
Investigating the Interplay of SARS-CoV-2 RNAemia and Peripheral Inflammation in Platelet Dysfunction During Acute SARS-CoV-2 Infection
by: Mariangela Scavone, et al.
Published: (2025-07-01) -
An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV
by: Hailong Guo, et al.
Published: (2023-12-01) -
Is The SARS-CoV2 Evolved in Human Being: A prospective Genetic Analysis
by: Salvatore Dimonte, et al.
Published: (2020-12-01) -
Adaptation of the Vaccine Prophylaxis Strategy to Variants of the SARS-CoV-2 Virus
by: Sofia M. Gulova, et al.
Published: (2025-07-01)